Leontieva OV, Blagosklonny MV (2014) Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion. Oncotarget 5, 12715-27 25587030

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T37-p - 4E-BP1 (human) ▲

Modsite: PPGDysttPGGtLFs SwissProt Entrez-Gene Orthologous residues 4E‑BP1 (human): T37‑p, 4E‑BP1 (mouse): T36‑p, 4E‑BP1 (rat): T36‑p, 4E‑BP1 (fruit fly): T37‑p, 4E‑BP1 (cow): T37‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes U0126 no change compared to control rapamycin no change compared to control U0126 no change compared to control Torin1 decrease

T46-p - 4E-BP1 (human) ▲

Modsite: GGtLFsttPGGtRII SwissProt Entrez-Gene Orthologous residues 4E‑BP1 (human): T46‑p, 4E‑BP1 (mouse): T45‑p, 4E‑BP1 (rat): T45‑p, 4E‑BP1 (fruit fly): T46‑p, 4E‑BP1 (cow): T46‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes U0126 no change compared to control rapamycin no change compared to control U0126 no change compared to control Torin1 decrease

T308-p - Akt1 (human) ▲

Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene Orthologous residues Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester no change compared to control Torin1 decrease U0126 decrease

T202-p - ERK1 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase in 10% FBS, slight induction without FBS rapamycin no change compared to control U0126 no change compared to control Torin1 no change compared to control

Y204-p - ERK1 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase in 10% FBS, slight induction without FBS rapamycin no change compared to control U0126 no change compared to control Torin1 no change compared to control

T185-p - ERK2 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase in 10% FBS, slight induction without FBS rapamycin no change compared to control U0126 no change compared to control Torin1 no change compared to control

Y187-p - ERK2 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase in 10% FBS, slight induction without FBS rapamycin no change compared to control U0126 no change compared to control Torin1 no change compared to control

T412-p - p70S6K (human) ▲

Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene Orthologous residues p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase U0126 decrease rapamycin decrease Torin1 decrease

T444-p - p70S6K (human) ▲

Modsite: RFIGsPRtPVsPVkF SwissProt Entrez-Gene Orthologous residues p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): S429‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase U0126 decrease

S447-p - p70S6K (human) ▲

Modsite: GsPRtPVsPVkFsPG SwissProt Entrez-Gene Orthologous residues p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): S430‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase U0126 decrease

S235-p - S6 (human) ▲

Modsite: IAKRRRLssLRAsts SwissProt Entrez-Gene Orthologous residues S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p, S6 (cow): S235‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase in presence and absense of 10% serum U0126 decrease rapamycin decrease Torin1 decrease

S236-p - S6 (human) ▲

Modsite: AKRRRLssLRAstsK SwissProt Entrez-Gene Orthologous residues S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p, S6 (cow): S236‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase in presence and absense of 10% serum U0126 decrease rapamycin decrease Torin1 decrease

S240-p - S6 (human) ▲

Modsite: RLssLRAstsKsEss SwissProt Entrez-Gene Orthologous residues S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p, S6 (fruit fly): S239‑p, S6 (cow): S240‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase in presence and absense of 10% serum U0126 no change compared to control rapamycin decrease Torin1 decrease

S244-p - S6 (human) ▲

Modsite: LRAstsKsEssQK__ SwissProt Entrez-Gene Orthologous residues S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p, S6 (fruit fly): V243‑p, S6 (cow): S244‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes phorbol_ester increase in presence and absense of 10% serum U0126 no change compared to control rapamycin decrease Torin1 decrease